Evolution of First-Line Immune Checkpoint Inhibition in Advanced or Metastatic Solid Tumors

This digital series explores the evolving first-line treatment landscape of advanced or metastatic solid tumors, including non-small cell lung cancer, with an emphasis on the use of immune checkpoint inhibitors alone or in combination with other treatment modalities.